TY - JOUR
T1 - Growth hormone secretory pattern in non-obese children and adolescents with Prader-Willi syndrome
AU - Grugni, Graziano
AU - Crinò, Antonino
AU - Pagani, Sara
AU - Meazza, Cristina
AU - Buzi, Fabio
AU - De Toni, Teresa
AU - Gargantini, Luigi
AU - Pilotta, Alba
AU - Pozzan, Giovanni B.
AU - Radetti, Giorgio
AU - Ragusa, Letizia
AU - Salvatoni, Alessandro
AU - Sartorio, Alessandro
AU - Bozzola, Mauro
PY - 2011/8/1
Y1 - 2011/8/1
N2 - The aetiology of impaired growth hormone (GH) secretion in Prader-Willi syndrome (PWS) remains controversial due to the common occurrence of obesity. To further clarify whether suboptimal GH secretion in PWS is an artefact of excess weight, we evaluated both GH immunological activity and GH bioactivity after arginine administration in 23 non-obese PWS patients [seven females, aged 6.9±0.9 years, body mass index (BMI) SDS 0.63±0.26], in comparison with a control group of 32 healthy subjects, matched for age, gender and BMI (10 females, aged 7.9±0.3 years, BMI SDS 0.21±0.20). Serum GH concentration was measured with a time-resolved immunofluorometric assay (IFMA), while GH bioactivity was evaluated by the Nb2 cell bioassay. Serum IGF-I concentrations were measured by double-antibody RIA. GH mean peak after pharmacological stimulation was significantly lower in PWS individuals compared with controls when measured either by IFMA (6.05±1.23 μg/L vs. 23.7±1.06 μg/L, p
AB - The aetiology of impaired growth hormone (GH) secretion in Prader-Willi syndrome (PWS) remains controversial due to the common occurrence of obesity. To further clarify whether suboptimal GH secretion in PWS is an artefact of excess weight, we evaluated both GH immunological activity and GH bioactivity after arginine administration in 23 non-obese PWS patients [seven females, aged 6.9±0.9 years, body mass index (BMI) SDS 0.63±0.26], in comparison with a control group of 32 healthy subjects, matched for age, gender and BMI (10 females, aged 7.9±0.3 years, BMI SDS 0.21±0.20). Serum GH concentration was measured with a time-resolved immunofluorometric assay (IFMA), while GH bioactivity was evaluated by the Nb2 cell bioassay. Serum IGF-I concentrations were measured by double-antibody RIA. GH mean peak after pharmacological stimulation was significantly lower in PWS individuals compared with controls when measured either by IFMA (6.05±1.23 μg/L vs. 23.7±1.06 μg/L, p
KW - GH bioactivity
KW - GH deficiency
KW - obesity
KW - Prader-Willi syndrome
UR - http://www.scopus.com/inward/record.url?scp=80052010891&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=80052010891&partnerID=8YFLogxK
U2 - 10.1515/JPEM.2011.269
DO - 10.1515/JPEM.2011.269
M3 - Article
C2 - 21932585
AN - SCOPUS:80052010891
VL - 24
SP - 477
EP - 481
JO - Journal of Pediatric Endocrinology and Metabolism
JF - Journal of Pediatric Endocrinology and Metabolism
SN - 0334-018X
IS - 7-8
ER -